Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
'Patients are Waiting'over 1 year ago
Patient Treatment & Travel: The Need for Stepped-Up Supportover 1 year ago
A Biosimilars Roadmap: Understanding Payer Perceptionsover 1 year ago
Avoiding the Digital Age is Hurting Research Effortsover 1 year ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 1 year ago
Yvonne Greenstreet: Answering the CallNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Augmentin XR Becomes First Approval Under Commissioner’s National Priority Voucher Pilot Program
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
EU Opportunities: How EMA Support Programs Can Slash Drug Market Entry Costs by 90%
4
FDA Approves Waskyra For Treatment of Wiskott-Aldrich Syndrome
5
